La cadena de opciones muestra datos clave de las opciones de acciones de Intelligent Living a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Intelligent Living..

Intelligent Living (NASDAQ:ILAG) Bolsa, Cadena de Opciones

Intelligent Living

Intelligent Living Application Group Inc is engaged in the business of manufacturing and selling mechanical locksets. The business is spread across the Unites States, Canada, Australia, and China. Majority of the revenue is generated from the United States.

Intelligent Living Application Group Inc. - Ordinary Shares

Intelligent Living Application Group Inc

<p>Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Allegro Microsystems, revealing an average target of $26.33, a high estimate of $31.00, and a low estimate of $22.00. This current average has decreased by 6.53% from the previous average price target of $28.17. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956894_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Allegro Microsystems by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Allegro Microsystems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Allegro Microsystems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Allegro Microsystems's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Allegro Microsystems's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ALGM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Allegro Microsystems analyst ratings.</strong></a></p>
<h2>All You Need to Know About Allegro Microsystems</h2>
<p>Allegro Microsystems Inc is a designer, developer, fabless manufacturer, and marketer of sensor ICs and application-specific analog power ICs for automotive and industrial markets. Its Sensor IC allows customers to precisely measure motion, speed, position, and current, and Power ICs include high-temperature and high-voltage capable motor drivers, power management, and LED driver ICs. Its products are divided into three categories such as SENSE which includes Current Sensors, Switches and Latches, and Interface ICs among others; REGULATE which includes Regulators, ClearPower Modules, and LED Drivers; and DRIVE which includes BLDC Drivers, Brush DC, and others. Key revenue for the company is generated from Greater China and the rest from the United States, Japan, Europe, and other regions.</p>
<h3>Key Indicators: Allegro Microsystems's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Allegro Microsystems's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-30.24%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-3.86%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Allegro Microsystems's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.73%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Allegro Microsystems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-0.47%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Allegro Microsystems's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.43</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

ALGM

The Analyst Verdict: Allegro Microsystems In The Eyes Of 6 Experts

<p>NiSun Intl Enterprise Dev (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>) reported quarterly earnings of $1.43 per share. This is a 67.94 percent decrease over earnings of $4.46 per share from the same period last year.  The company reported $340.20 million in sales this quarter. This is a 12.02 percent decrease over sales of $386.67 million the same period last year.</p>


Earnings

News

NISN

NiSun Intl Enterprise Dev FY EPS $1.43 Down From $4.46 YoY, Sales $340.20M Down From $386.67M YoY

<p>Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) in the last three months.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $86.36, a high estimate of $112.00, and a low estimate of $73.00. This current average represents a 9.91% decrease from the previous average price target of $95.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956885_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A clear picture of DuPont de Nemours's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duffy Fischer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$73.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$74.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$76.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$103.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DuPont de Nemours. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DuPont de Nemours compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of DuPont de Nemours's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of DuPont de Nemours's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on DuPont de Nemours analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind DuPont de Nemours</h2>
<p>DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics, water, construction, safety and protection, automotive, and healthcare industries. DuPont plans to spin off its electronics business by the end of 2025.</p>
<h3>DuPont de Nemours's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> DuPont de Nemours's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>6.69%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> DuPont de Nemours's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-3.82%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> DuPont de Nemours's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-0.5%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-0.32%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.31</strong>, DuPont de Nemours adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing DuPont de Nemours: Insights From 14 Financial Analysts

<p>Albany Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Albany Intl will report an <strong>earnings per share</strong> (EPS) of $0.63.</p>
<p>The market awaits Albany Intl's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS missed by $0.08 in the last quarter, leading to a 6.41% drop in the share price on the following day.</p>
<p>Here's a look at Albany Intl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.66</td>
<td>0.57</td>
<td>0.91</td>
<td>0.87</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.58</td>
<td>0.80</td>
<td>0.89</td>
<td>0.90</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>-4.0%</td>
<td>2.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956883_0.png" alt="eps graph" /></p>
<h3>Market Performance of Albany Intl's Stock</h3>
<p>Shares of Albany Intl were trading at $66.58 as of April 28. Over the last 52-week period, shares are down 18.69%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Take on Albany Intl</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Albany Intl.</p>
<p>Analysts have provided Albany Intl with 3 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $82.33, suggesting a potential 23.66% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Enerpac Tool Group, Symbotic and Standex International, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Enerpac Tool Group, with an average 1-year price target of $53.0, suggesting a potential 20.4% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Symbotic, with an average 1-year price target of $29.14, suggesting a potential 56.23% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Standex International, with an average 1-year price target of $220.8, suggesting a potential 231.63% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for Enerpac Tool Group, Symbotic and Standex International are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albany International</td>
<td>Buy</td>
<td>-11.34%</td>
<td>$90.32M</td>
<td>1.83%</td>
</tr>
<tr>
<td>Enerpac Tool Group</td>
<td>Outperform</td>
<td>5.12%</td>
<td>$73.43M</td>
<td>5.20%</td>
</tr>
<tr>
<td>Symbotic</td>
<td>Neutral</td>
<td>35.21%</td>
<td>$80.04M</td>
<td>-1.77%</td>
</tr>
<tr>
<td>Standex International</td>
<td>Outperform</td>
<td>6.40%</td>
<td>$71.45M</td>
<td>0.13%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Albany Intl ranks at the bottom for Revenue Growth among its peers. It is at the top for Gross Profit. For Return on Equity, it is at the bottom. Overall, Albany Intl is positioned in the middle compared to its peers.</p>
<h3>All You Need to Know About Albany Intl</h3>
<p>Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.</p>
<h3>A Deep Dive into Albany Intl's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Albany Intl's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-11.34%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Albany Intl's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>6.16%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Albany Intl's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.83%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Albany Intl's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>1.04%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.41</strong>.</p>
<p><a href="https://www.benzinga.com/quote/AIN/earnings"><strong>To track all earnings releases for Albany Intl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What's Next: Albany Intl's Earnings Preview

<p>In the latest quarter, 28 analysts provided ratings for Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">16</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">11</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $177.11, a high estimate of $216.00, and a low estimate of $133.00. Marking an increase of 9.75%, the current average surpasses the previous average price target of $161.38. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956875_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A clear picture of Axsome Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$193.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$216.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$212.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$192.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$153.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Cerena Chen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$176.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$167.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Marc Goodman</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$143.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Axsome Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Axsome Therapeutics analyst ratings.</strong></a></p>
<h2>About Axsome Therapeutics</h2>
<p>Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.</p>
<h3>Understanding the Numbers: Axsome Therapeutics's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Axsome Therapeutics's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>66.04%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-63.08%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Axsome Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-99.94%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Axsome Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-13.26%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Axsome Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>3.38</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AXSM

Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)

<p>Ratings for Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $108.8, a high estimate of $125.00, and a low estimate of $89.00. This current average represents a 0.18% decrease from the previous average price target of $109.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956861_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Q2 Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Adam Hotchkiss</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$106.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Alexander Sklar</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$108.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Andrew Schmidt</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Q2 Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Q2 Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Q2 Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Q2 Holdings's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/QTWO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Q2 Holdings analyst ratings.</strong></a></p>
<h2>About Q2 Holdings</h2>
<p>Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.</p>
<h3>A Deep Dive into Q2 Holdings's Financials</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Q2 Holdings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>12.91%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Q2 Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.09%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Q2 Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.03%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.01%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Q2 Holdings's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.05</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


QTWO

A Glimpse Into The Expert Outlook On Q2 Holdings Through 10 Analysts

<p>Weave Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEAV#NYSE">WEAV</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $16.75, a high estimate of $20.00, and a low estimate of $14.00. Experiencing a 9.46% decline, the current average is now lower than the previous average price target of $18.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956851_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Weave Communications by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Sklar</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Alexander Sklar</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Weave Communications. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Weave Communications compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Weave Communications's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Weave Communications's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WEAV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Weave Communications analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Weave Communications</h2>
<p>Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue primarily from subscription services.</p>
<h3>Weave Communications's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Weave Communications's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>18.55%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Weave Communications's net margin is impressive, surpassing industry averages. With a net margin of <strong>-12.39%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Weave Communications's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-9.88%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Weave Communications's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-3.52%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Weave Communications's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.84</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


WEAV

4 Analysts Assess Weave Communications: What You Need To Know

<p><strong>Live Nation Entertainment's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) short percent of float has risen 5.94% since its last report. The company recently reported that it has <strong>14.57 million shares sold short</strong>, which is 9.28% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 4.83 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Live Nation Entertainment Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956831_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Live Nation Entertainment has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Live Nation Entertainment's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Live Nation Entertainment's peer group average for short interest as a percentage of float is 7.95%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

How Do Investors Really Feel About Live Nation Entertainment?

<p>In the preceding three months, 7 analysts have released ratings for Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $26.14, a high estimate of $36.00, and a low estimate of $16.00. Experiencing a 10.39% decline, the current average is now lower than the previous average price target of $29.17. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956829_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of Nurix Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Faisal Khurshid</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nurix Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nurix Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Nurix Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Nurix Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NRIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Nurix Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Delving into Nurix Therapeutics's Background</h2>
<p>Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.</p>
<h3>Nurix Therapeutics: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Nurix Therapeutics showcased positive performance, achieving a revenue growth rate of <strong>11.26%</strong> as of 28 February, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Nurix Therapeutics's net margin excels beyond industry benchmarks, reaching <strong>-305.38%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Nurix Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-11.18%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Nurix Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-8.77%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.06</strong>, Nurix Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NRIX

Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views

<p><strong>Somnigroup International's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGI#NYSE">SGI</a>) short percent of float has risen 9.13% since its last report. The company recently reported that it has <strong>30.46 million shares sold short</strong>, which is 15.06% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 5.78 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Somnigroup International Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956825_0_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Somnigroup International has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Somnigroup International's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Somnigroup International's peer group average for short interest as a percentage of float is 6.35%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Looking Into Somnigroup International's Recent Short Interest

<p>Mr. Cooper Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) has outperformed the market over the past 10 years by 3.56% on an annualized basis producing an average annual return of 13.8%. Currently, Mr. Cooper Gr has a market capitalization of $7.36 billion. </p>
<p><strong>Buying $100 In COOP:</strong> If an investor had bought $100 of COOP stock 10 years ago, it would be worth <strong>$367.05</strong> today based on a price of $115.03 for COOP at the time of writing.</p>
<h3>Mr. Cooper Gr's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956825_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


COOP

Here's How Much $100 Invested In Mr. Cooper Gr 10 Years Ago Would Be Worth Today

<p>In the current session, the stock is trading at $26.65, after a <strong>0.87%</strong> spike. Over the past month, <strong>Fiverr Intl Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVRR#NYSE">FVRR</a>)</strong> stock increased by <strong>11.18%</strong>, and in the past year, by <strong>27.94%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1745956823_0.png" alt="Past Year Chart" /></p>

<h3>Fiverr Intl P/E Ratio Analysis in Relation to Industry Peers</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Compared to the aggregate P/E ratio of the <strong>57.43</strong> in the Professional Services industry, Fiverr Intl Inc. has a lower P/E ratio of <strong>55.04</strong>. Shareholders might be inclined to think that  the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1745956823_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


Intraday Update

Markets

FVRR

P/E Ratio Insights for Fiverr Intl

<p><strong>AstraZeneca's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NYSE">AZN</a>) short percent of float has fallen 41.18% since its last report. The company recently reported that it has <strong>6.33 million shares sold short</strong>, which is 0.2% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.0 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>AstraZeneca Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956820_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for AstraZeneca has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing AstraZeneca's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AstraZeneca's peer group average for short interest as a percentage of float is 3.85%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


What Does the Market Think About AstraZeneca?

<p>Technology giant<strong> Microsoft Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) could be one of the most-watched stocks for the week when the company reports third-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Wednesday</a>.</p>
<p>Here are the earnings estimates, a look at what analysts are saying and key items to watch.</p>
<p><strong>Earnings Estimates: </strong>Analysts expect Microsoft to report third-quarter revenue of $68.44 billion, up from $61.86 billion in last year's third quarter, according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0429">from Benzinga Pro.</a></p>
<p>The company has beaten analyst revenue estimates in eight straight quarters and nine of the last 10 quarters overall.</p>
<p>Analysts expect Microsoft to report third-quarter earnings per share of $3.22, up from $2.94 in last year's third quarter. Microsoft has beaten analyst earnings per share estimates in 10 straight quarters.</p>
<p><strong>What Experts Are Saying:</strong> Freedom Capital Markets Chief Global Strategist Jay Woods emphasized the importance of Microsoft's financial results in a weekly <a href="https://jaywoods.substack.com/">newsletter</a>.</p>
<p>"Considering we are dealing with the top market caps in the world, their price impact will move the markets. All but META are in both the Dow and S&amp;P 500 and all four stocks are the top holdings in their specific sector ETFs," Woods said of Meta Platforms, Microsoft, Apple and Amazon.com.</p>
<p>Woods said all four have recently hit bear market territory and have "much room to reverse to get back to old highs."</p>
<p>"MSFT shares are 16% below their highs and flat for the last year. The company continues to spend on AI and investors want to see how this investment is being integrated into their product suite and what impact that will have on revenue."</p>
<p>Woods said another key focus will be on Microsoft's cloud services performance. "Growth with Azure is expected to bolster its cloud operations.&#8221;</p>
<p>Wedbush analyst Dan Ives <a href="https://www.benzinga.com/25/04/45001386/dan-ives-software-the-only-safety-blanket-amid-the-storm-of-tariffs">recently highlighted</a> Microsoft as one of several software stocks that could be part of what he called a "security blanket" from the "Category 5" storm that includes trade wars, tariffs and geopolitical uncertainties.</p>
<p>He noted that with the supply chain "visibly clouded," companies with software are a safer bet, with Microsoft being one example. The analyst also said the "AI party is just getting started," with a prediction of $1 trillion in incremental spending for the sector over the next decade helping companies like Microsoft.</p>
<p>Goldman Sachs analyst Kash Rangan was one of several analysts to <a href="https://www.benzinga.com/25/04/44977884/goldman-trims-microsoft-price-target-to-450-but-sticks-with-bullish-gen-ai-growth-thesis">cut the price target</a> on Microsoft stock ahead of earnings, taking the target from $500 to $400 while reiterating a Buy rating.</p>
<p>The analyst said Microsoft still remains a compelling name in software but is concerned about several potential near-term headwinds.</p>
<p>Rangan is specifically cautious about Microsoft's guidance as there could be "some downside risk" if non-AI growth slows.</p>
<p><span style="box-sizing: border-box; margin: 0px; padding: 0px;">KeyBanc Capital analyst Jackson Ader<a href="https://www.benzinga.com/analyst-ratings/downgrades/25/04/44874447/microsoft-analyst-lowers-rating-flags-slower-growth-flat-valuation-outlook" target="_blank" rel="noopener"> recently downgraded Microsoft </a>stock from &#8220;Overweight&#8221; to &#8220;Sector Weight&#8221;</span> with no price target.</p>
<p>The analyst said some durable macro themes could play out during the on-calendar season for Microsoft, with caution in the company's guidance.</p>
<p>While the current quarter was holding up fine, conversations with Microsoft marketing partners indicated concerns for the rest of the year, Ader said.</p>
<p><strong>Key Items to Watch</strong>: Cloud and AI are likely to be the most-watched segments in Microsoft's earnings report, along with items to watch for management commentary.</p>
<p>In <a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details">the second quarter</a>, Microsoft's Intelligent Cloud segment saw revenue increase by 19% year-over-year.</p>
<p>"We are innovating across our tech stack and helping customers unlock the full ROI of AI to capture the massive opportunity ahead," Microsoft CEO <strong>Satya Nadella</strong> said after second-quarter results.</p>
<p>Nadella said Microsoft's AI business had surpassed an annual run rate of $13 billion.</p>
<p>As mentioned by Woods, Microsoft could be one of the most important stocks for the week due to its presence in several top indexes. The stock report could make the <strong>SPDR S&amp;P 500 ETF Trust</strong> (SPY) and<strong> SPDR Dow Jones Industrial Average ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) ETFs volatile.</p>
<p>Microsoft is the second-largest holding in the SPY at 6.2% of assets and is the third-largest holding in the DIA at 6.0% of assets.</p>
<p><strong>MSFT Price Action:</strong> Microsoft stock is up 0.6% to $393.35 on Tuesday versus a 52-week trading range of $344.79 to $468.35. Microsoft stock is down 6.0% year-to-date in 2025 and down 2.2% over the last year.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/04/45043339/stock-of-the-day-will-microsoft-bring-the-entire-market-higher">Stock Of The Day: Will Microsoft Take The Entire Market Higher?</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Analyst Color

Price Target

Previews

Reiteration

Tech

SPDR Dow Jones Industrial Average ETF Trust

MSFT

Microsoft Q3 Earnings Preview: Cloud, AI, Guidance Top Items Analysts Highlight To Watch

WIIM

MSTR

Strategy shares are trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and announced a price target of $480.

Progressive shares are trading higher after Morgan Stanley raised its price target on the stock from $310 to $320 and maintained an Overweight rating.

Ecolab shares are trading higher after the company issued FY25 adjusted EPS guidance with its midpoint above estimates.

PANW

Palo Alto Networks shares are trading higher after the company announced it partnered with AT&T to introduce secure connectivity solutions for business customers.

<p><a href="https://www.bloomberg.com/news/articles/2025-04-29/electronic-arts-lays-off-hundreds-cancels-titanfall-game?sref=y3YMCJ4e" title="https://www.bloomberg.com/news/articles/2025-04-29/electronic-arts-lays-off-hundreds-cancels-titanfall-game?sref=y3YMCJ4e">https://www.bloomberg.com/news/articles/2025-04-29/electronic-arts-lays-off-hundreds-cancels-titanfall-game?sref=y3YMCJ4e</a></p>


Comments

Intelligent Living

Intelligent Living (ILAG) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL